DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s00432-015-1987-1, but it redirected us to https://link.springer.com/article/10.1007/s00432-015-1987-1. The analysis below is for the second page.

Title[redir]:
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid | Journal of Cancer Research and Clinical Oncology
Description:
Purpose The retinoic acid signaling pathway, crucial for differentiation, is silenced by epigenetic mechanisms in many cancers. Epigenetically active, chromatin-modifying agents offer a novel treatment approach, by reactivating aberrantly silenced genes in tumor cells and by sensitizing them to subsequent treatments. We hypothesized that the treatment of non-small cell lung cancer (NSCLC) cells with a histone deacetylase (HDAC) inhibitor may prime them to the antiproliferative and differentiating activity of all-trans retinoic acid. Methods The NSCLC cell lines A549, NCI-H460 and HCC827 were treated with ATRA (2 µM) and the pan-HDAC inhibitor panobinostat (LBH589; 10–35 nM). Results While treatment with ATRA alone showed only very modest effects, panobinostat reduced cellular proliferation by at least 50 %. Notably, the combination of panobinostat and ATRA had additive and synergistic effects, respectively, on growth inhibition and differentiation, with almost no cytotoxicity. Effects were strongest in A549, followed by the EGFR-mutant HCC827, and least pronounced in NCI-H460. Global histone H3 acetylation was strongly induced by panobinostat; interestingly, ATRA alone had also an effect on histone acetylation, which was synergistically enhanced when the HDAC inhibitor was added. The combination of the two drugs additively decreased expression of phospho-ERK and phospho-AKT, whereas p53 and p21CIP1/WAF1 proteins were both induced. Conclusion Panobinostat sensitized, to varying degrees, all three cell lines to the antiproliferative and differentiating effects of ATRA, with synergistic histone H3 acetylation. Combination therapy with an epigenetic drug and ATRA may offer an alternative to aggressive chemotherapy even in primary ATRA-insensitive tumors, such as adenocarcinomas of the lung.

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't see how the site brings in money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, article, cancer, google, scholar, lung, cas, cell, central, nonsmall, acid, histone, cells, retinoic, inhibitor, clin, oncol, research, epigenetic, effects, treatment, panobinostat, combination, therapy, analysis, differentiation, deacetylase, atra, acetylation, access, phase, patients, human, res, freiburg, privacy, cookies, content, journal, lines, lübbert, expression, trial, doijco, egfr, leukemia, publish, search, clinical, antiproliferative,

Topics {✒️}

wnt7a induces e-cadherin small-cell lung cancer month download article/chapter human cml-bc cells chromatin-modifying agents offer trans-retinoic acid treatment intermediate-risk myelodysplastic syndromes long-term complete remission potentiates tnf-induced activation induction histone deacetylase trans retinoic acid trans-retinoic acid pan-hdac inhibitor panobinostat lung cancer cells small-cell carcinoma primary atra-insensitive tumors retinoic acid receptors continuous tumor-cell line nadja blagitko-dorfs clinical oncology aims full article pdf human lung carcinoma histone acetylation open-label translational cancer research histone deacetylase privacy choices/manage cookies global cancer statistics leukemia cell differentiation selective inhibitor entinostat hsp90 inhibitor 17-aag comprehensive expression analysis article greve decarboxylation cell properties stem cell transplantation related subjects e-cadherin pathway retinoic acid phase ii trial german research foundation check access instant access cell lines chemotherapy based signaling networks assembled vimentin expression predicts acute promyelocytic leukemia lung cancer 81 lung cancer article log

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid
         description: The retinoic acid signaling pathway, crucial for differentiation, is silenced by epigenetic mechanisms in many cancers. Epigenetically active, chromatin-modifying agents offer a novel treatment approach, by reactivating aberrantly silenced genes in tumor cells and by sensitizing them to subsequent treatments. We hypothesized that the treatment of non-small cell lung cancer (NSCLC) cells with a histone deacetylase (HDAC) inhibitor may prime them to the antiproliferative and differentiating activity of all-trans retinoic acid. The NSCLC cell lines A549, NCI-H460 and HCC827 were treated with ATRA (2 µM) and the pan-HDAC inhibitor panobinostat (LBH589; 10–35 nM). While treatment with ATRA alone showed only very modest effects, panobinostat reduced cellular proliferation by at least 50 %. Notably, the combination of panobinostat and ATRA had additive and synergistic effects, respectively, on growth inhibition and differentiation, with almost no cytotoxicity. Effects were strongest in A549, followed by the EGFR-mutant HCC827, and least pronounced in NCI-H460. Global histone H3 acetylation was strongly induced by panobinostat; interestingly, ATRA alone had also an effect on histone acetylation, which was synergistically enhanced when the HDAC inhibitor was added. The combination of the two drugs additively decreased expression of phospho-ERK and phospho-AKT, whereas p53 and p21CIP1/WAF1 proteins were both induced. Panobinostat sensitized, to varying degrees, all three cell lines to the antiproliferative and differentiating effects of ATRA, with synergistic histone H3 acetylation. Combination therapy with an epigenetic drug and ATRA may offer an alternative to aggressive chemotherapy even in primary ATRA-insensitive tumors, such as adenocarcinomas of the lung.
         datePublished:2015-05-26T00:00:00Z
         dateModified:2015-05-26T00:00:00Z
         pageStart:2171
         pageEnd:2180
         sameAs:https://doi.org/10.1007/s00432-015-1987-1
         keywords:
            Epigenetic therapy
            Non-small cell lung cancer
            Retinoic acid
            Chromatin modification
            Histone acetylation
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig7_HTML.gif
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:141
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gabriele Greve
               affiliation:
                     name:University of Freiburg Medical Center
                     address:
                        name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
                     name:University of Freiburg
                     address:
                        name:Faculty of Biology, University of Freiburg, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Insa Schiffmann
               affiliation:
                     name:University of Freiburg Medical Center
                     address:
                        name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
                     name:University of Freiburg
                     address:
                        name:Faculty of Medicine, University of Freiburg, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael Lübbert
               affiliation:
                     name:University of Freiburg Medical Center
                     address:
                        name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
                     name:DKTK, German Consortium for Translational Cancer Research
                     address:
                        name:DKTK, German Consortium for Translational Cancer Research, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid
      description: The retinoic acid signaling pathway, crucial for differentiation, is silenced by epigenetic mechanisms in many cancers. Epigenetically active, chromatin-modifying agents offer a novel treatment approach, by reactivating aberrantly silenced genes in tumor cells and by sensitizing them to subsequent treatments. We hypothesized that the treatment of non-small cell lung cancer (NSCLC) cells with a histone deacetylase (HDAC) inhibitor may prime them to the antiproliferative and differentiating activity of all-trans retinoic acid. The NSCLC cell lines A549, NCI-H460 and HCC827 were treated with ATRA (2 µM) and the pan-HDAC inhibitor panobinostat (LBH589; 10–35 nM). While treatment with ATRA alone showed only very modest effects, panobinostat reduced cellular proliferation by at least 50 %. Notably, the combination of panobinostat and ATRA had additive and synergistic effects, respectively, on growth inhibition and differentiation, with almost no cytotoxicity. Effects were strongest in A549, followed by the EGFR-mutant HCC827, and least pronounced in NCI-H460. Global histone H3 acetylation was strongly induced by panobinostat; interestingly, ATRA alone had also an effect on histone acetylation, which was synergistically enhanced when the HDAC inhibitor was added. The combination of the two drugs additively decreased expression of phospho-ERK and phospho-AKT, whereas p53 and p21CIP1/WAF1 proteins were both induced. Panobinostat sensitized, to varying degrees, all three cell lines to the antiproliferative and differentiating effects of ATRA, with synergistic histone H3 acetylation. Combination therapy with an epigenetic drug and ATRA may offer an alternative to aggressive chemotherapy even in primary ATRA-insensitive tumors, such as adenocarcinomas of the lung.
      datePublished:2015-05-26T00:00:00Z
      dateModified:2015-05-26T00:00:00Z
      pageStart:2171
      pageEnd:2180
      sameAs:https://doi.org/10.1007/s00432-015-1987-1
      keywords:
         Epigenetic therapy
         Non-small cell lung cancer
         Retinoic acid
         Chromatin modification
         Histone acetylation
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-015-1987-1/MediaObjects/432_2015_1987_Fig7_HTML.gif
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:141
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gabriele Greve
            affiliation:
                  name:University of Freiburg Medical Center
                  address:
                     name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
                  name:University of Freiburg
                  address:
                     name:Faculty of Biology, University of Freiburg, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Insa Schiffmann
            affiliation:
                  name:University of Freiburg Medical Center
                  address:
                     name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
                  name:University of Freiburg
                  address:
                     name:Faculty of Medicine, University of Freiburg, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael Lübbert
            affiliation:
                  name:University of Freiburg Medical Center
                  address:
                     name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
                  name:DKTK, German Consortium for Translational Cancer Research
                  address:
                     name:DKTK, German Consortium for Translational Cancer Research, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:141
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Freiburg Medical Center
      address:
         name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
         type:PostalAddress
      name:University of Freiburg
      address:
         name:Faculty of Biology, University of Freiburg, Freiburg, Germany
         type:PostalAddress
      name:University of Freiburg Medical Center
      address:
         name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
         type:PostalAddress
      name:University of Freiburg
      address:
         name:Faculty of Medicine, University of Freiburg, Freiburg, Germany
         type:PostalAddress
      name:University of Freiburg Medical Center
      address:
         name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
         type:PostalAddress
      name:DKTK, German Consortium for Translational Cancer Research
      address:
         name:DKTK, German Consortium for Translational Cancer Research, Heidelberg, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gabriele Greve
      affiliation:
            name:University of Freiburg Medical Center
            address:
               name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
               type:PostalAddress
            type:Organization
            name:University of Freiburg
            address:
               name:Faculty of Biology, University of Freiburg, Freiburg, Germany
               type:PostalAddress
            type:Organization
      name:Insa Schiffmann
      affiliation:
            name:University of Freiburg Medical Center
            address:
               name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
               type:PostalAddress
            type:Organization
            name:University of Freiburg
            address:
               name:Faculty of Medicine, University of Freiburg, Freiburg, Germany
               type:PostalAddress
            type:Organization
      name:Michael Lübbert
      affiliation:
            name:University of Freiburg Medical Center
            address:
               name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
               type:PostalAddress
            type:Organization
            name:DKTK, German Consortium for Translational Cancer Research
            address:
               name:DKTK, German Consortium for Translational Cancer Research, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
      name:Faculty of Biology, University of Freiburg, Freiburg, Germany
      name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
      name:Faculty of Medicine, University of Freiburg, Freiburg, Germany
      name:Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany
      name:DKTK, German Consortium for Translational Cancer Research, Heidelberg, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(192)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.64s.